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Abstract 
Aims 
Non-alcoholic fatty liver disease (NAFLD) is common in type 2 diabetes and associated 
with higher risk of cardiovascular disease. This study aimed to determine whether alanine 
aminotransferase (ALT) or gamma-glutamyltransferase (GGT), as markers of liver health 
and NAFLD, might predict cardiovascular events in this population.  
Methods 
Data from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study 
were analysed to examine the relationship between liver enzymes and incident 
cardiovascular events (nonfatal myocardial infarction, stroke, coronary and other 
cardiovascular death, coronary or carotid revascularization) over 5 years.  
Results 
ALT had a linear inverse relationship with the first cardiovascular event on study. After 
adjustment, for every standard deviation higher baseline ALT (13.2U/L), the risk of an 
event was 7%(95%CI 4–13, P=0.02) lower. Participants with ALT below and above the 
reference range 8–41 U/L for women and 9–59 U/L for men, had a hazard ratio of an event 
of 1.86(95%CI, 1.12–3.09) and 0.65(95%CI, 0.49–0.87), respectively (P=0.001). No 
relationship was found for GGT.  
Conclusions 
The data may indicate that in type 2 diabetes — associated with higher ALT due to 
prevalent NAFLD — lower ALT is a marker of hepatic or systemic frailty rather than 
health. 
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Introduction 
Non-alcoholic fatty liver disease (NAFLD), ranging from simple steatosis to cirrhosis, is 
strongly associated with diabetes and the metabolic syndrome [1]. While not universally 
accepted, the potential systemic implications of NAFLD are increasingly being recognized 
[1]. This would include the clinically important, independent association between NAFLD 
and cardiovascular disease that has been asserted by many, although not all, groups [1-3]. A 
logical step to explore this association, has been to examine liver enzymes as predictors of 
cardiovascular events [4], and their use as part of risk-algorithms for cardiovascular disease 
has been proposed [5]. Alanine aminotransferase (ALT), has a good correlation with liver 
fat, as assessed by magnetic resonance spectroscopy, and is a viewed as a valid marker of 
necroinflammation in NAFLD [4, 6]. Both ALT and gamma glutamyl-transferase (GGT) 
are associated with the metabolic syndrome, insulin resistance, and diabetes and its 
development, but their relationship with cardiovascular outcomes is more complex [1, 2, 4, 
5, 7-14]. 
This study sought to examine the association of baseline ALT and GGT with time to total 
cardiovascular events in participants of the Fenofibrate Intervention and Event Lowering in 
Diabetes (FIELD) study, designed to assess the effect of fenofibrate on cardiovascular 
disease events in people with diabetes [15]. 
Patients and Methods 
The study was a subsidiary analysis of the FIELD study—a double-blind, placebo-
controlled trial done in 63 centres in Australia, New Zealand, and Finland [15]. In brief, 
9795 participants aged 50–75 years with type 2 diabetes according to WHO criteria [16] 
were randomly allocated between 1998 and 2000 to once-daily micronized fenofibrate or 
placebo. Participants had an initial total-cholesterol concentration 3.0–6.5 mmol/L, plus 
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either total-cholesterol/HDL-cholesterol ratio ≥4.0 or plasma triglyceride concentration 
1.0–5.0 mmol/L, and not on lipid-modifying therapy at study entry. Exclusion criteria 
included: blood creatinine >130 μmol/L, chronic liver disease, a cardiovascular event 
within 3 months of recruitment, ALT >2 times the upper limit of normal and a recent 
history of alcohol abuse. Total cardiovascular events was a pre-specified secondary 
endpoint and included nonfatal myocardial infarction, total stroke, cardiovascular death, 
coronary and carotid revascularization [15]. 
Baseline characteristics 
A full clinical assessment was performed at baseline. A history of macrovascular disease 
was defined as any self-reported history of myocardial infarction, angina, percutaneous 
transluminal coronary angioplasty, coronary artery bypass grafting, stroke, claudication, 
peripheral vascular disease, or peripheral revascularization. Nephropathy was defined as the 
presence of albuminuria [15]. Alcohol consumption pattern was classified as none, 
infrequent (special occasion to once/week) or regular (≥2 times/week), as data were lacking 
for grams taken per week. 
Laboratory parameters 
All samples were analysed at one of two laboratories: SA Pathology, Adelaide, Australia or 
the laboratory of the National Public Health Institute, Helsinki, Finland. Both laboratories 
participated in national quality assurance schemes. ALT and GGT were measured 16 weeks 
and ALT again 6 weeks before randomization. The average of the two ALT measurements 
was used for analysis. All specimens were stored immediately at -20°C and shipped 
expediently (within 7 days) for processing. ALT and GGT assays used standard 
colorimetric techniques consistent with the guidelines of the International Foundation of 
Clinical Chemistry (IFCC) [17].  
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Statistical analysis  
Analyses were performed on an intention-to-treat basis using SPSS v21, and confirmed on 
SAS v9.3. Due to the non-normal distribution of both ALT and GGT, their relationship 
with baseline characteristics was determined using Spearman’s correlation for continuous 
variables and the Wilcoxon rank–sum or Kruskal–Wallis test for categorical variables. To 
assess the relationship between baseline ALT and GGT and time to first cardiovascular 
event, Cox proportional-hazards regression was used to compute hazard ratios (HRs) and 
95% confidence intervals (CIs). Examined by quintiles and deciles, the data were consistent 
with a linear relationship between ALT and cardiovascular events (Fig. 1), and so 
continuous ALT (per one SD) was used in predictive models. With similar techniques, 
GGT had a nonlinear relationship to the time to first cardiovascular event, and so the 
primary analysis was by quintiles (Fig. 1). All models were adjusted for assignment to 
fenofibrate and the following pre-specified baseline variables: age, gender, diabetes 
duration, hypertension, nephropathy, macrovascular disease, current-smoker status, waist-
hip-ratio, HbA1c, triglyceride levels, HDL-cholesterol (HDL-c) and LDL-cholesterol 
(LDL-c).  
For ALT, in post hoc analysis, the multivariable model was further individually adjusted 
for laboratory used, alcohol consumption pattern or C-peptide, fasting glucose, and diabetes 
treatment category (diet, oral antidiabetic therapy or insulin±oral therapy). Penalized Cox 
modelling with an estimate of treatment effect was then used to adjust for statin therapy use 
on study [18]. To explore whether ALT might be acting as a marker of systemic frailty, the 
model was also adjusted for reported activity (very light, light, moderate, heavy or very 
heavy) [19]. Interactions among all predefined baseline variables, in addition to laboratory 
used, alcohol consumption pattern, C-peptide, fasting glucose, and diabetes treatment 
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category, were tested to identify any differential effect of ALT between various categories, 
with P<0.05 considered significant. If positive interactions were found, appropriate sub-
analysis was then performed. 
The multivariable GGT quintile model was further adjusted individually for alcohol 
consumption pattern and baseline ALT. Given no clear relationship between GGT and time 
to first cardiovascular event after adjustment, interaction testing for GGT was limited to 
specific variables: assignment to fenofibrate use, age, sex, history of macrovascular disease, 
alcohol consumption pattern, laboratory used and ALT. 
To further explore the relationships seen in primary models, the population was divided 
into normal, low, and high ALT and GGT by established international reference ranges, 
published by Ceriotti et al on behalf of the IFCC [17]. Kaplan–Meier graphs were produced 
for time to first total cardiovascular event for both ALT and GGT by category. To explore 
differences among these groups in baseline characteristics, including presence of the 
metabolic syndrome (ATP III criteria [20]) and in measures of homeostasis model 
assessment of insulin resistance (HOMA-IR), highly-sensitive C-reactive protein (hsCRP) 
and platelets as markers of insulin resistance, inflammation, and hypersplenism, 
respectively, the Wilcoxon rank–sum or the Kruskal–Wallis test was used for continuous 
data and the chi-squared test for categorical variables. HRs for the first cardiovascular event 
on study using these categories were calculated using Cox regression. Models were 
univariate only, given the limited number of events in the low ALT and GGT categories. 
Ethics 
All participants provided written informed consent. The study protocol was approved by 
local and national ethics committees and was undertaken in accordance with the 
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Declaration of Helsinki and Good Clinical Practice Guidelines. The original trial was 
registered with the International Standard Randomised Controlled Trial Number (ISRCTN) 
64783481. 
Results 
Baseline associations with ALT and GGT 
The average age of the cohort was 62±7 years. Median (interquartile range, (IQR)) diabetes 
duration, HbA1c and BMI were 5(2–10) years, 52(43-62) mmol/mol (6.9(6.1–7.8) %), and 
29.8(26.8–33.5) kg/m2, respectively. In regard to medication, 2608(27%) were on diet, 
5841(59%) were on oral antidiabetic therapy only, and 1346(14%) were on insulin ± oral 
therapy. 
The median baseline ALT was 24(IQR 18–33) U/L and the median baseline GGT was 
29(IQR 21–44) U/L. Lower ALT, but not GGT, was associated with a prior history of 
macrovascular disease and current smoking. GGT had a positive correlation with hsCRP 
(Table 1 and eTable 1). 
With normal ALT defined as 8–41 U/L for women and 9–59 U/L for men [17], 1%(n=64) 
had low ALT and 6%(n=550) had high ALT. Of participants with low, normal, and high 
ALT, 15/64(23%), 1230/9181(13%) and 50/550(9%) had cardiovascular events on study, 
respectively (Table 2, eTable 1). Of those with low ALT, 40% of events were death due to 
cardiovascular disease, compared to 17% in those with normal ALT, and 8% in those with 
high ALT (Table 2). With normal GGT defined as 6–40 U/L for women and 12–68 U/L for 
men [17], 1%(n=76) of the cohort had low GGT and 16%(n=1566) had high GGT. Of 
participants with low, normal, and high GGT, 6/70(8%), 1100/8153(13%), and 
189/1566(12%) had cardiovascular events, respectively. Data for basic demographics and 
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metabolic syndrome presence, HOMA-IR, hsCRP, platelet count, and cardiovascular deaths 
as proportions of first cardiovascular events on study for ALT and GGT categories are 
shown in eTable 1. 
Baseline ALT and first cardiovascular event 
In univariate analysis, the risk of a cardiovascular event was  8(3-13)% lower for each SD 
(13.2 U/L) higher ALT at baseline (P=0.004). This relationship remained significant after 
adjustment (Table 3). The unadjusted HRs for cardiovascular events on study in those 
above and below the reference ranges for ALT when compared to those with normal ALT 
were 0.65(95% CI, 0.49–0.87) and 1.86(95% CI, 1.12–3.09), respectively (P=0.001) (Fig. 
2, eTable 1). 
The primary model was adjusted for other possible contributing factors, which did not 
affect the relationship between ALT and cardiovascular events (Table 3). A positive 
interaction was found for HDL-c and ALT for the relationship between ALT and 
cardiovascular events (P=0.03 for interaction).  To further explore this, sub-analysis was 
performed with the Cohort divided into HDL-c quintiles (Table 4). 
Baseline GGT and first cardiovascular event 
GGT quintiles were significantly related to time to first cardiovascular event in univariate 
analysis (P=0.001). This relationship was attenuated after adjustment, although, 
qualitatively, the lowest GGT quintile appeared to have a lower risk of events than the 
remainder of the cohort (Fig. 1). Adjustment for alcohol consumption pattern had no effect 
on the model. Interestingly, statistical associations of GGT quintiles with cardiovascular 
events were significant after adjustment for ALT (P=0.04, Table 5). No interaction was 
found for assignment to fenofibrate, age, sex, alcohol consumption pattern, laboratory used, 
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history of macrovascular disease or ALT. The unadjusted HRs for the first cardiovascular 
event on study for those with low or high GGT when compared to those with normal GGT 
were 0.56(0.25–1.25) and 0.90(0.7–1.05), respectively (Fig. 2, eTable 1).  
Discussion 
ALT had an inverse relationship with the first cardiovascular event on study in people with 
type 2 diabetes, without known chronic liver disease, and with ALT not greater than twice 
the upper limit of normal. No clear association between GGT and the time to first 
cardiovascular event was found. 
Given that NAFLD is considered a potential risk factor for cardiovascular disease, our 
finding might seem counterintuitive; however, similar results have been reported in regard 
to both mortality and cardiovascular events in several other studies using cohorts with 
different characteristics and not defined by diabetes [21] [22] [9]
,
[23] [24]. Our results are, 
however, contrary to the findings of other studies that have found either a positive or no 
association between ALT and cardiovascular disease events and mortality [2, 7, 10]. The 
reasons for these differences could include the population selected for study, in particular 
their dissimilar overall cardiovascular risk and range of ALT levels, and the duration of 
follow-up and the methods of analysis, including whether linear or threshold analysis was 
used for ALT. 
ALT is commonly higher in type 2 diabetes and often presumed to represent NAFLD, 
which has a prevalence of 70% in diabetes overall and can be significantly higher when 
obesity is also present [1, 4]. ALT may also be elevated due to other factors [1, 4]. For 
example, higher ALT in diabetes may also be the result of upregulated gluconeogenesis 
through hepatic insulin resistance, in addition to the production of ALT within adipose 
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tissue when insulin resistance and obesity coexist (as demonstrated in mice) [4]. Perhaps 
similar to the increased risk for mortality that has been demonstrated in those with type 2 
diabetes with low or normal body weight when compared to those who are in the 
overweight category [25, 26], a low ALT in our cohort may not be associated with health 
but may rather exist as a marker of a more severe phenotype, without significant insulin 
resistance or steatosis, consisting of reduced β-cell function, an at-risk genetic profile 
and/or overall biological frailty and co-morbidity [19, 26].  
Low ALT has been linked to frailty in several studies, although our limited analysis to 
explore the role of ALT as a potential marker of frailty was not useful. For example, Ruhl 
et al showed that adjusted appendicular lean mass, potentially associated with sarcopenia, 
was lower among the lowest ALT deciles in 15 028 subjects whose body composition was 
measured by dual-energy X-ray absorptiometry [9]. Couteur et al, found that lower ALT 
was associated with older age and lower survival over 4.9 years of follow-up in 1673 
community-dwelling men aged >70 years [19]. This finding was attenuated by adjustment 
for frailty, with ALT independently associated with frailty as defined by a formal frailty 
index.  
Low ALT may also be a marker of reduced liver reserve, perhaps enhancing an 
environment of increased oxidative stress, as a result of biological aging and/or increased 
liver fibrosis due to non-alcoholic steatohepatitis [8, 27]. Indeed, while results are mixed, 
the severity of liver disease may increase cardiovascular risk in NAFLD [1, 28], with the 
presence of simple steatosis alone having no adverse implications [29]. Moreover, ALT 
levels are thought to be 22–64% heritable, with ALT loci near genes involved in glucose 
and lipid metabolism, inflammation and immunity, and the biogenesis of mitochondria 
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[30], as a potential link between ALT and clinically important genes that may affect 
cardiovascular risk [30]. The potential for greater risk reduction by statin therapy in those 
with a higher ALT is also possible [22]
,
[12], perhaps through a greater reduction in small 
LDL particles or other adverse lipid measures [11, 12], although adjustment for statin 
therapy did not significantly change our results. Lower ALT has also been associated with 
several markers of systemic inflammation in one study [11] and with higher NT proBNP in 
another [31]. 
Clinical and biochemical associations with increasing ALT in our analysis were similar to 
those previously described [1, 8, 11], and included positive associations with measures of 
adiposity, the metabolic syndrome, insulin resistance, and poorer glycaemic control. Those 
with a known history of macrovascular disease and those who were current smokers or 
users of insulin, all factors that may potentially increase future cardiovascular event risk, 
had lower ALT than their respective reference group. ALT also had an inverse association 
with age. Despite these associations, which may link low ALT to cardiovascular events, no 
interaction was found for these factors, and appropriate adjustments were included in 
multivariable models. A positive interaction was found for HDL-c, with subsequent quintile 
analysis suggesting that the relationship was most pronounced in those with HDL-c ≤ 0.88 
mmol/L, consistent with more significant dyslipidaemia. No significant interaction was 
found for fenofibrate therapy, excluding a differential treatment effect. 
Surprisingly, we did not find a relationship between GGT and on-study cardiovascular 
events after adjustment. As GGT is presumed to be a less specific marker of liver fat and 
NAFLD per se, and rather may reflect the metabolic syndrome [4, 5, 13], this may be 
explained by the effects of adjustment for variables that would also reflect an adverse 
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metabolic profile. Interestingly, further adjustment for alcohol consumption pattern did not 
significantly affect the model. On the other hand, adjustment for ALT did strengthen the 
relationship between GGT and cardiovascular events, perhaps by selecting for elevated 
GGT due to liver fibrosis (by adjusting for steatosis), or by selecting for GGT as a marker 
of oxidative stress ± atherosclerotic burden, rather than liver pathology [5, 8, 14, 30]. 
Despite the statistically negative finding, the positive direction of the association between 
GGT and cardiovascular events is consistent with current literature. GGT has been 
positively associated with incident vascular events and mortality in several studies but not 
all [5, 8, 9, 13, 19].  
Strengths of our analysis include the use of prospective data from a large, well-defined 
cohort, with pre-specified outcomes. In addition, intra-individual variation in ALT was 
accommodated by using an average of two independent samples. Weaknesses of our 
findings relate to the problems of secondary analysis. High ALT and known chronic liver 
disease were exclusion criteria and so the effects of comorbidity due to liver disease are 
likely to be attenuated in this data set. Also, follow-up was a median of 5 years, which is 
perhaps insufficient time to see the effects of an adverse metabolic phenotype associated 
with higher baseline ALT. Participants selected for study for a clinical trial may have been 
healthier than a community dwelling population with diabetes. ALT and GGT were 
measured at two laboratories, and differences in analytical technique and geographic 
variation may not have been fully adjusted for [17]. Alcohol consumption by grams per 
week, steatosis presence, or NAFLD severity could not be corrected for, nor could 
assessment by a formal frailty index. Reference ranges used meant that groups above and 
below normal had small numbers. Normal values for liver enzymes have not been 
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established. These reference ranges were chosen as they were developed from an 
international cohort, with strict attention to population selected and analytical technique 
[17]. The analysis using these reference ranges was illustrative only, to complement 
primary models. 
While NAFLD has been linked to cardiovascular disease, in populations with type 2 
diabetes, a lower ALT may predict cardiovascular events. Study of the mechanisms behind 
lower ALT being associated with cardiovascular outcomes in various at-risk groups is 
needed, with a particular emphasis on formal assessment of biological frailty and co-
morbidity, NAFLD severity, and lipid parameters in cohorts under study. Use of ALT or 
GGT in predictive algorithms for cardiovascular disease is premature. 
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Tables 
Table 1: Clinical and biochemical associations with baseline alanine aminotransferase (ALT) 
and gamma glutamyltransferase (GGT) levels 
 ALT GGT 
Baseline characteristic (number, % of 
cohort) 
Median and IQR 
(U/L) or 
correlation 
coefficient P 
Median and IQR 
(U/L) or 
correlation 
coefficient P 
Age (years) –0.21 <0.001 –0.13 <0.001 
Sex  <0.001  <0.001 
 Female (n=3657, 37%) 21 (16–29)  26 (19–40)  
 Male 25 (19–35)  31 (22–46)  
Country of recruitment  <0.001  <0.001 
 Australia or New Zealand (n=8402, 86%) 23 (18–32)  29 (21–43)  
 Finland 26 (19–37)  32 (22–48)  
Waist-hip ratio 0.26 <0.001 0.25 <0.001 
Body mass index (kg/m
2
) 0.19 <0.001 0.21 <0.001 
Diabetes duration (years) –0.04 <0.001 –0.05 <0.001 
Smoking status  <0.001  <0.001 
 Non-smoker (n=3929, 40%) 23 (17–32)  27 (19–40)  
 Ex-smoker (n=4944, 51%) 25 (19–34)  30 (22–46)  
 Current smoker (n=922, 9%) 23 (17–31)  31 (22–47)  
Alcohol intake  <0.001  <0.001 
 None (n=2691, 28%) 23 (17–31)  27 (20–40)  
 Infrequent (n=4604, 47%) 24 (18–32)  28 (20–42)  
 Regular (n=2494, 25%) 25 (19–35)  34 (24–52)  
Metabolic syndrome (n=8101, 83%) 24 (18–34) <0.001 30 (22–46) <0.001 
No metabolic syndrome 21 (16–28)  25 (17–36)  
Comorbidity     
 Hypertension (n=5546, 57%) 24 (18–33)  0.34 30 (22–46) <0.001 
 No hypertension 24 (18–32)  28 (20–41)  
 Known macrovascular disease (n=2131, 
22%) 
23 (18–31) 
<0.001 
29 (21–45) 
0.08 
 No known macrovascular disease 24 (18–33)  29 (21–44)  
 Nephropathy (n=2508, 26%) 24 (18–34) 0.007 32 (23–48) <0.001 
 No nephropathy 24 (18–32)  28 (20–42)  
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 ALT GGT 
Baseline characteristic (number, % of 
cohort) 
Median and IQR 
(U/L) or 
correlation 
coefficient P 
Median and IQR 
(U/L) or 
correlation 
coefficient P 
Medication     
 Metformin (n=4794, 49%) 25 (18–35) <0.001 30 (22–46) <0.001 
 No metformin 23 (18–31)  28 (20–42)  
 Sulfonylurea (n=4433, 45%) 25 (19–34) <0.001 30 (22–47) <0.001 
 No sulfonylurea 23 (18–31)  28 (20–42)  
 Insulin (n=1346, 14%) 23 (17–30) 0.003 28 (19–43) <0.001 
 No insulin 24 (18–33)  29 (21–44)  
Diabetes treatment overall  <0.001  <0.001 
 Diet only 22.5 (17.5–30.5)  28 (20–40)  
 Oral hypoglycaemic 24.5 (18.0–34.0)  30 (22–46)  
 Insulin ± oral hypoglycaemic 22.5 (17.0–30.0)  28 (19–43)  
Biochemistry     
 HbA1c (% or mmol/mol) 0.12 <0.001 0.12 <0.001 
 Fasting glucose (mmol/L) 0.16 <0.001 0.14 <0.001 
 C-peptide (nmol/L) 0.29 <0.001 0.30 <0.001 
 HDL-C (mmol/L) –0.15 <0.001 –0.09 <0.001 
 LDL-C (mmol/L) –0.09 <0.001 –0.09 <0.001 
 Triglyceride (mmol/L) 0.15 <0.001 0.21 <0.001 
 Apolipoprotein A1 (g/L) –0.10 <0.001 –0.01 0.27 
 Apolipoprotein B (g/L) 0.03 0.001 0.07 <0.001 
 Lipoprotein a (g/L) –0.10 <0.001 –0.10 <0.001 
 Highly-sensitive C-reactive protein (mg/L) –0.01 0.49 0.18 <0.001 
 Uric acid (μmol/L) 0.11 <0.001 0.14 <0.001 
 HOMA insulin resistance 0.32 <0.001 0.33 <0.001 
 Platelets (x10
9
/L) –0.14 <0.001 –0.09 <0.001 
 ALT (U/L) –  0.51 <0.001 
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Table 2: Type of first cardiovascular event on study by alanine aminotransferase (ALT) 
category as determined by reference ranges set by Ceriotti et al [17]. 
Type of cardiovascular event 
ALT below 
reference range 
ALT within 
reference range* 
ALT above 
reference range 
Death due to coronary heart disease 5 (33%) 154 (13%) 3 (6%) 
Death due to other cardiovascular disease 1 (7%) 49 (4%) 1 (2%) 
Coronary artery bypass grafting 4 (27%) 224 (18%) 6 (12%) 
Percutaneous transluminal coronary 
angioplasty 
1 (7%) 190 (15%) 14 (28%) 
Nonfatal coronary infarction 3 (20%) 317 (26%) 15 (30%) 
Nonfatal stroke 1 (7%) 257 (21%) 8 (16%) 
Carotid revascularization 0 39 (3%) 3 (6%) 
Total number of events/total in group 15/64 1230/9181 50/550 
* Using these reference ranges, normal ALT, 8–41 U/L for women and 9–59 U/L for men. 
Data are presented as n (%) within each group. 
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Table 3: Relationship between baseline alanine aminotransferase (ALT) and first 
cardiovascular event  
Model 
Hazard 
ratio
a
 
95% confidence 
interval P 
Unadjusted (n=9795, 1295 events) 0.92 0.87–0.97 0.004 
Adjusted (n=9765, 1291 events)
b
 0.92 0.87–0.98 0.01 
Adjusted plus central laboratory (n=9765, 1291 events) 0.92 0.87–0.98 0.01 
Adjusted plus alcohol consumption pattern (n=9759, 1288 
events) 
0.92 0.87–0.98 0.01 
Adjusted plus C-peptide, fasting glucose (to replace HbA1c) and 
diabetes treatment (n=9658, 1281 events) 
0.91 0.85–0.97 0.003 
Adjusted plus statin therapy (penalized Cox model) (n=9765, 
1291 events) 
0.92 0.87 – 0.98 0.01 
Adjusted for reported level of activity (n=9648, 1273 events) 0.92 0.86 - 0.98 0.01 
a
 Per 1 standard deviation higher baseline ALT. 
b
 The adjusted model includes: assignment to treatment with fenofibrate and baseline: age, sex, diabetes 
duration, known macrovascular disease, hypertension, nephropathy, current smoker status, waist-hip-ratio, 
HbA1c, triglyceride level, high-density lipoprotein cholesterol and low-density lipoprotein cholesterol.  
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Table 4. Relationship between baseline alanine aminotransferase (ALT) and cardiovascular 
(CVD) events by High-density lipoprotein cholesterol (HDL-c) quintiles using Cox 
Proportional Hazards Regression analysis 
 
 
ALT per SD (13.2 U/L) 
 
Variable (CVD events/total number of individuals in analysis) HR (95% CI) p value 
HDL-c ≤ 0.88mmol/L (364/1968) 0.86 (0.77-0.97) 0.01 
HDL-c > 0.88 mmol/L and ≤ 1.01 mmol/L (298/2037) 0.88 (0.78-1.00) 0.05 
HDL-c > 1.01 mmol/L and ≤ 1.12 mmol/L (234/1901) 0.91 (0.79-1.04) 0.17 
HDL-c > 1.12  mmol/L and ≤ 1.28 mmol/L (214/1916) 1.07 (0.94-1.22) 0.31 
HDL-c > 1.28 mmol/L (181/1943) 0.99 (0.84-1.16) 0.88 
P value for trend in effect of ALT by HDL-c quintiles = 0.022 
a 
model adjusted for: assignment to treatment with fenofibrate and baseline age, sex, diabetes duration, known 
macrovascular disease, hypertension, nephropathy, current smoker, waist-hip-ratio, HbA1c, triglycerides, 
high-density lipoprotein cholesterol and low-density lipoprotein cholesterol. HR, hazard ratio; CI, confidence 
interval; SD, standard deviation 
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Table 5: Relationship between baseline alanine aminotransferase (ALT) as a linear variable 
and gamma glutamyltransferase (GGT) in quintiles and time to first cardiovascular event 
 
P HR 
95.0% CI for HR 
Lower Upper 
ALT as linear variable in adjusted model*     
 ALT per SD (per 13.2 U/L) 0.01 0.92 0.87 0.98 
GGT quintiles in adjusted model     
 GGT ≤19 U/L 0.10    
 GGT >19 and ≤26 U/L  1.13 0.95 1.35 
 GGT >26 and ≤33 U/L  1.28 1.07 1.54 
 GGT >33 and ≤49 U/L  1.10 0.91 1.32 
 GGT >49 U/L  1.10 0.91 1.33 
ALT (linear) and GGT (quintiles) in adjusted 
model and corrected for each other 
    
 ALT per SD (per 13.2 U/L) 0.003 0.90 0.84 0.97 
 GGT ≤19 U/L 0.04    
 GGT >19 and ≤26 U/L  1.16 0.97 1.38 
 GGT >26 and ≤33 U/L  1.34 1.11 1.61 
 GGT >33 and ≤49 U/L  1.18 0.98 1.43 
 GGT >49 U/L  1.24 1.01 1.52 
 
 * With adjustment for: assignment to treatment with fenofibrate and baseline age, sex, diabetes duration, 
known macrovascular disease, hypertension, nephropathy, current smoker, waist-hip-ratio, HbA1c, 
triglycerides, high-density lipoprotein cholesterol and low-density lipoprotein cholesterol. HR, hazard ratio; 
CI, confidence interval; SD, standard deviation 
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Figure Legends 
 
Figure 1 
Adjusted beta coefficients obtained by Cox regression analysis for A. alanine 
aminotransferase (ALT), and B. gamma-glutamyltransferase (GGT) by quintiles (using the 
median of each quintile on the x axis) with line of best fit illustrated on the ALT model. 
Models were adjusted for the pre-specified variables—assignment to treatment with 
fenofibrate and baseline characteristics: age, sex, diabetes duration, known macrovascular 
disease, hypertension, nephropathy, current smoker status, waist-hip ratio, HbA1c, 
triglyceride level, high-density lipoprotein cholesterol and low-density lipoprotein 
cholesterol. The 95%, 2-sided, confidence intervals were created using Plummer's method 
of constructing floating confidence intervals. Numbers refer to quintiles 1 to 5. HR, hazard 
ratio; U/L, units per litre. 
Figure 2 
Kaplan-Meier plots for time to first total cardiovascular event on study by A. alanine 
aminotransferase (ALT), and B. gamma-glutamyltransferase (GGT) category. Normal 
ALT, 8–41 U/L for women and 9–59 U/L for men. Normal GGT, 6–40 U/L for women and 
12–68 U/L for men. Log-rank P=0.001 for difference across categories for ALT and 
P=0.16 for difference across categories for GGT. HR, hazard ratio; RR, reference range. 
